OraSure
This article was originally published in The Gray Sheet
Executive Summary
OraQuick Advance rapid HIV-1/2 antibody test launch is planned for November, following a summer CLIA waiver for the oral fluid test. OraSure gained approval for the HIV-2 component of the test in March and the HIV-1 claim in June (1"The Gray Sheet" May 3, 2004, In Brief)...
You may also be interested in...
OraSure HIV test nears market entry
Firm targets "mid-summer" launch for its combined OraQuick HIV-1/2 rapid oral fluid test. Prior to launch, OraSure must obtain licensing rights for the test's HIV-2 marker from Bio-Rad and a Clinical Laboratory Improvement Amendments (CLIA) waiver for the diagnostic's oral fluid component. Further, the firm needs FDA clearance for the test's HIV-2 portion; the HIV-1 part received clearance March 26. OraSure plans to submit HIV-2 data and completed clinical tests for the CLIA waiver by June (1"The Gray Sheet" March 29, 2004, p. 3)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.